CMG-DIGITAL
25.4.2022 01:02:06 CEST | Business Wire | Press release
Global digital design and smart production agency CMG Digital is today relaunching as part of an ongoing evolution of its company brand.
The agency, based in Croatia, with a presence in the UK and the US, now has a new vision and is dedicating itself to putting humanity back into digital.
The acceleration of digital adoption during the pandemic brought many positives to the digital space, including investment, faster development, new services and virtual worlds. At the same time, it has also tackled issues around security, privacy, sustainability and inefficiencies.
More significantly, the acceleration of digital has seen a move towards automation and away from humanisation in digital.
The relaunched CMG Digital is the answer: an agency dedicated to supporting clients to ensure they can maximise success in digital within this context.
The new vision will also be accompanied by a new look. With the agency debuting a new logo, theme and tone of voice. The updated visual identity will represent the evolved brand values.
Putting humanity at the core of its company was an easy decision for the agency, which boasts two thirds of women holding the top management positions as well as women making up more than 55% of the overall employees. CMG Digital also boasts a mental health program called MindGiving to support the team: this includes yoga classes, managing stress workshops, meeting limits, no meeting Friday as well as additional health insurance.
Explaining the new vision, Ana Tolić, President of CMG said:
“We are both delighted and excited to enter this new era of CMG Digital history and focus on our mission of putting humanity back into digital.
“Over the course of the pandemic the lightning-fast adoption of digital meant the space quickly became inhuman and cold.
“We are an agency that recognises that we can’t replace the people's side of things with a platform, and that relationships are critical to success. We believe in focusing on B2H – Business to Human.”
The relaunch will also keep digital sustainability at the heart of the agency.
CMG Digital is known for setting the industry tone when it comes to sustainability. Historically, the agency standardised recycling long before it became compulsory. Now, it is leading the way once more and focussing on standardising its approach to digital sustainability.
As global-to-local experts, CMG Digital puts a strong focus on maximising content life through reuse, recycling and repurposing to reduce the digital waste of its clients.
This focus is allowing CMG Digital to spread its message, educate and upskilling clients and brands in digital sustainability as well as digital inclusivity.
CMG Digital hopes that its position as a leader in its field will enable it to set the tone and encourage other agencies to follow its example. The agency is a powerhouse in its industry, credited with delivering over 50,000 projects, working with more than 200 global brands and delivering to over 100 markets worldwide. Since 2001 it has been the digital custodian of some of the world’s most valuable brands across the globe, and today leading digital deployment for multinational corporations such as P&G, GSK, Novartis, ConvaTec, Cloetta, Edgewell and Rimac.
CMG Digital believes its relaunch will help it better achieve its overall goal of empowering brands to scale their global message to the local level with consistency and pace.
-ENDS-
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005009/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
